Fortress Biotech, Inc. (FBIO) Stock Price

FBIOStock

$1.87−31.75%52W

Market Cap$62.37M

P/E9.15x

PEG Ratio—

Div yield—

Beta1.24

FBIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-32.63%

Price vs S&P 500 (4W)-21.08%

VGM Score57.83

P/E Ratio (Annual)9.15x

Book Value / Share (Quarterly)$4.93

P/TBV (Annual)5.10x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-5.82%

Cash Flow / Share (Quarterly)$3.78

Price vs S&P 500 (YTD)-60.83%

Gross Margin (TTM)65.59%

Net Profit Margin (TTM)163.32%

EPS (TTM)$2.91

10-Day Avg Trading Volume0.28M

EPS Excl Extra (TTM)$2.91

Revenue Growth (5Y)6.77%

EPS (Annual)$0.24

Dividend / Share (Annual)$0.02

ROI (Annual)6.23%

Gross Margin (Annual)66.92%

Net Profit Margin (5Y Avg)-69.82%

Cash / Share (Quarterly)$5.90

P/E Basic Excl Extra (TTM)0.56x

Revenue Growth QoQ (YoY)14.04%

P/E Normalized (Annual)9.15x

ROA (Last FY)3.67%

Revenue Growth TTM (YoY)15.46%

EBITD / Share (TTM)$-0.75

ROE (5Y Avg)-144.95%

Operating Margin (TTM)-42.74%

Cash Flow / Share (Annual)$-2.10

P/B Ratio0.38x

P/B Ratio (Quarterly)0.62x

Net Income / Employee (Annual)$87,400

EV / Revenue (TTM)-1.38x

Net Interest Coverage (TTM)-3.18x

ROA (TTM)42.98%

EV / EBITDA (TTM)-0.82x

EPS Incl Extra (Annual)$0.24

Current Ratio (Annual)2.49x

Quick Ratio (Quarterly)3.76x

3-Month Avg Trading Volume0.49M

52-Week Price Return-31.75%

P/E Incl Extra (TTM)0.56x

Revenue / Employee (TTM)$877,800

Tangible BV / Share (Quarterly)$4.16

P/S Ratio (Annual)0.99x

Asset Turnover (Annual)0.34x

52-Week High$4.53

Operating Margin (5Y Avg)-194.96%

EPS Excl Extra (Annual)$0.24

CapEx CAGR (5Y)25.86%

Tangible BV CAGR (5Y)3.44%

26-Week Price Return-22.73%

Quick Ratio (Annual)2.20x

13-Week Price Return-44.35%

Total Debt / Equity (Annual)1.19x

Current Ratio (Quarterly)3.96x

Enterprise Value$-94.61M

Revenue / Share Growth (5Y)-24.91%

Asset Turnover (TTM)0.26x

Book Value / Share Growth (5Y)-36.92%

Revenue / Employee (Annual)$811,100

Inventory Turnover (Annual)1.74x

Pretax Margin (Annual)-53.01%

Cash / Share (Annual)$2.53

3-Month Return Std Dev50.29%

Gross Margin (5Y Avg)62.38%

Net Income / Employee (TTM)$1,433,600

ROE (Last FY)13.66%

Net Interest Coverage (Annual)9.58x

EPS Basic Excl Extra (Annual)$0.24

Receivables Turnover (TTM)2.64x

EV / Free Cash Flow (TTM)-0.75x

Total Debt / Equity (Quarterly)0.24x

EPS Incl Extra (TTM)$2.91

Receivables Turnover (Annual)3.16x

ROI (TTM)71.68%

Dividend Growth Rate (5Y)-54.94%

P/S Ratio (TTM)0.91x

Pretax Margin (5Y Avg)-192.91%

Revenue / Share (Annual)$2.27

Tangible BV / Share (Annual)$0.71

Forward P/E115.39x

Price vs S&P 500 (52W)-47.28%

P/E Ratio (TTM)0.56x

Year-to-Date Return-48.91%

5-Day Price Return-11.37%

EPS Normalized (Annual)$0.24

ROA (5Y Avg)-22.03%

Net Profit Margin (Annual)10.77%

Month-to-Date Return-12.62%

Cash Flow / Share (TTM)$-25.80

EBITD / Share (Annual)$-1.39

Operating Margin (Annual)-68.12%

LT Debt / Equity (Annual)1.19x

P/CF (TTM)0.50x

ROI (5Y Avg)-44.39%

P/E Excl Extra (TTM)0.56x

LT Debt / Equity (Quarterly)0.21x

EPS Basic Excl Extra (TTM)$2.91

P/TBV (Quarterly)0.73x

Payout Ratio (Annual)9.74%

P/B Ratio (Annual)2.28x

Dividend / Share (TTM)$0.02

Inventory Turnover (TTM)2.24x

Pretax Margin (TTM)213.03%

Book Value / Share (Annual)$1.59

Price vs S&P 500 (13W)-47.03%

Dividend Yield (TTM)0.80%

Beta1.24x

Revenue / Share (TTM)$2.15

ROE (TTM)103.52%

52-Week Low$1.84

vGradeB

gGradeC

mGradeD

vgmGradeC

FBIO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.20	-$0.08	+60.00%(+$0.12)
Q1 2026	May 14, 2026	-$0.22	$2.82	+1381.82%(+$3.04)
Q4 2025	Mar 31, 2026	$0.11	-$0.21	-290.91%(-$0.32)
Q3 2025	Nov 14, 2025	-$0.63	$0.11	+117.60%(+$0.74)
Q2 2025	Aug 14, 2025	-$0.31	-$0.51	-65.29%(-$0.20)

FBIO Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.13

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
FBIOFortress Biotech, Inc.	B	C	D	0.9x	15.5%	65.6%	—	$1.87
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Fortress Biotech, Inc.

Fortress Biotech is a biopharmaceutical company focused on acquiring, developing, and commercializing dermatology and therapeutic products. Its portfolio includes key dermatology brands—Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm—which represent the majority of revenues. The company also operates in oncology and other therapeutic sectors through its subsidiaries.